title: European League against rheumatism - selected presentation and poster a highlights June 11th to 13th 2013.
abstract: BACKGROUND
  The heterogeneous pathology of many autoimmune diseases warrants the continual discovery and development of new drugs. Drawing on selected oral presentations and selected poster displays, this article highlights some new developments in the pharmacological validation of molecular targets implicated in inflammatory autoimmune disease and may be of direct importance to scientists working in this field.
  
  
  METHODS
  This report describes the current state of the pharmacology of selected drugs and targets which may have utility in modulating immune function and autoimmune inflammatory disease.
  
  
  CONCLUSIONS
  Many new molecules are progressing through clinical development for the treatment of rheumatological diseases. The value of the basic nonclinical and clinical research presented is to further pharmacological knowledge of the molecule, better understand the benefit-risk associated with clinical development and to assist in supporting the potential position of a new drug in the current treatment paradigm.
authors.affiliation: Inflammation, Neuroscience and Respiratory Global Medicines Development, AstraZeneca R&D , Mereside, Alderley Park, Macclesfield, SK10 4TG England , UK +44 0 1625 582828 ; Martin.Braddock@astrazeneca.com.
authors.forename: Martin
authors.initials: M
authors.lastname: Braddock
mesh_terms: D000818:Animals; D001327:Autoimmune Diseases / Q000188:drug therapy / Q000276:immunology / Q000382:microbiology; D006801:Humans; D012216:Rheumatic Diseases / Q000188:drug therapy / Q000276:immunology / Q000382:microbiology